Evogene Ltd. (EVGN)

Market Cap	9.66M
Revenue (ttm)	8.02M
Net Income (ttm)	-2.75M
Shares Out	8.72M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,061
Open	1.130
Previous Close	1.100
Day's Range	1.106 - 1.140
52-Week Range	0.950 - 2.420
Beta	1.57
Analysts	Strong Buy
Price Target	3.50 (+208.37%)
Earnings Date	Nov 20, 2025

About EVGN

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 117
• Stock Exchange: NASDAQ
• Ticker Symbol: EVGN
• Website: https://www.evogene.com

Financial Performance

In 2024, Evogene's revenue was $8.51 million, an increase of 50.90% compared to the previous year's $5.64 million. Losses were -$16.49 million, -30.96% less than in 2023.

Analyst Summary

According to one analyst, the rating for EVGN stock is "Strong Buy" and the 12-month stock price target is $3.5.

Price Target

$3.5

(208.37% upside)

Analyst Consensus: Strong Buy